Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
| Revenue (TTM) | $569.61M |
| Gross Profit (TTM) | $463.58M |
| EBITDA | $-50.05M |
| Operating Margin | -39.50% |
| Return on Equity | -335.80% |
| Return on Assets | -5.94% |
| Revenue/Share (TTM) | $10.81 |
| Book Value | $3.98 |
| Price-to-Book | 28.72 |
| Price-to-Sales (TTM) | 12.02 |
| EV/Revenue | 12.12 |
| EV/EBITDA | 341.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 43.30% |
| Shares Outstanding | $60.98M |
| Float | $52.46M |
| % Insiders | 1.39% |
| % Institutions | 114.54% |
Volatility is currently contracting
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals NASDAQ: MIRM executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MIRM and any ticker you trade — then tracks every position and per-strategy win rate.
